Suppr超能文献

大鼠中的胃泌素与胃肠嗜铬样细胞类癌

Gastrin and gastric enterochromaffin-like cell carcinoids in the rat.

作者信息

Carlsson E, Havu N, Mattsson H, Ekman L

机构信息

Gastrointestinal Research, AB Hässle, Mölndal, Sweden.

出版信息

Digestion. 1990;47 Suppl 1:17-23; discussion 49-52. doi: 10.1159/000200510.

Abstract

Life-long administration (greater than or equal to 2 years) of a number of long-acting gastric acid inhibitors (including H2-receptor antagonists, omeprazole and ciprofibrate) has been associated with the development of gastric enterochromaffin-like cell (ECL cell) carcinoids in rats. It has been postulated that they are a consequence of some unique property of the longer-acting acid inhibitors. There is, however, a great deal of evidence to support the hypothesis that these gastric ECL cell carcinoids develop as a result of life-long hypergastrinaemia in rats. Several lines of investigation reported here show that gastric ECL cell hyperplasia occurs when gastrin levels are increased without the use of acid-inhibiting drugs. In rats, hypergastrinaemia developed after 4 weeks' administration of exogenous gastrin (4 micrograms/kg/h). The number of gastric ECL cells per visual field had increased to 250 compared with 180 in the controls. Long-term hypergastrinaemia, induced by partial gastric corpectomy, increased plasma gastrin levels from 200 to 800 pg/ml and the density of gastric ECL cells increased from 190 to 310 cells/visual field 10 weeks after the operation. Importantly, gastric ECL cell hyperplasia, which was produced in rats by administration of omeprazole, 14 mg/kg/day for 1 year, was fully reversible following normalization of gastrin levels. Until now, gastric ECL cell carcinoids have not been reported in studies of shorter-acting, reversible H2-receptor antagonists such as ranitidine, perhaps because the correct staining techniques (i.e. Grimelius and Sevier-Munger silver stains) have not been used.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

多种长效胃酸抑制剂(包括H2受体拮抗剂、奥美拉唑和环丙贝特)的终身给药(大于或等于2年)已与大鼠胃肠嗜铬样细胞(ECL细胞)类癌的发生相关。据推测,它们是长效酸抑制剂某些独特特性的结果。然而,有大量证据支持这样的假设,即这些胃ECL细胞类癌是大鼠终身高胃泌素血症的结果。此处报告的几项研究表明,在不使用抑酸药物的情况下,当胃泌素水平升高时会发生胃ECL细胞增生。在大鼠中,外源性胃泌素(4微克/千克/小时)给药4周后出现高胃泌素血症。与对照组的180个相比,每个视野的胃ECL细胞数量增加到了250个。部分胃切除术诱导的长期高胃泌素血症使血浆胃泌素水平从200 pg/ml升高到800 pg/ml,术后10周胃ECL细胞密度从190个/视野增加到310个/视野。重要的是,大鼠通过每天14毫克/千克的奥美拉唑给药1年产生的胃ECL细胞增生,在胃泌素水平恢复正常后完全可逆。到目前为止,在雷尼替丁等短效、可逆性H2受体拮抗剂的研究中尚未报告胃ECL细胞类癌,这可能是因为未使用正确的染色技术(即Grimelius和Sevier-Munger银染)。(摘要截断于250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验